( S ( NP-SBJ ( NNS Analysts ) ) ( VP ( VBD said ) ( SBAR ( IN that ) ( S ( NP-SBJ ( NP ( NNP Merck ) ( CC & ) ( NNP Co. ) ) ( NP ( NNP Eli ) ( NNP Lilly ) ( CC & ) ( NNP Co. ) ) ( NP ( NNP Warner-Lambert ) ( NNP Co. ) ) ( CC and ) ( NP ( NP ( DT the ) ( NNP Squibb ) ( NNP Corp. ) ( NN unit ) ) ( PP ( IN of ) ( NP ( NNP Bristol-Myers ) ( NNP Squibb ) ( NNP Co. ) ) ) ) ) ( DT all ) ( VP ( VBD benefited ) ( PP-CLR ( IN from ) ( NP ( NP ( JJ strong ) ( NNS sales ) ) ( PP ( IN of ) ( NP ( NP ( ADJP ( RB relatively ) ( JJ new ) ) ( JJ higher-priced ) ( NNS medicines ) ) ( SBAR ( WHNP-1 ( WDT that ) ) ( S ( VP ( VBP provide ) ( NP ( JJ wide ) ( NN profit ) ( NNS margins ) ) ) ) ) ) ) ) ) ) ) ) ) )